ABSTRACT Aim: Gather 'proof-of-concept' evidence of the adverse developmental potential of cotinine (a seemingly benign biomarker of recent nicotine/tobacco smoke exposure).
INTRODUCTION
A pregnant passive smoker ingests cumulatively far less of the semivolatile toxin nicotine than a pregnant active smoker, yet offspring of the former exhibit a disproportionate anomaly in postural blood pressure compensation, a finding difficult to reconcile with exposure to nicotine per se notwithstanding its potency as a cardiovascular toxin (1) . Most (80%) inhaled or ingested nicotine is rapidly broken down in the body to cotinine. This minor structural variant (and anagram) of nicotine is historically considered to be relatively 'benign-inert', that is to lack significant pharmacological, cardiovascular or other side effects even at blood levels 10-fold higher than that attained by active smoking (2, 3) . Cotinine eventually passes out of the body in urine, but compared to its parent compound, blood levels rise far higher (>five-to 10-fold) and remain high for longer by virtue of slow body elimination (half-life = 19-24 hours vs.
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Key notes
Cotinine is a biomarker of recent passive smoking and is also a by-product of nicotine replacement therapy (NRT). Early-life exposure to this substance at real-life levels permanently alters blood vessel tone and blood pressure control and slows the heart during sleep. The risks posed by perinatal exposure to cotinine are preventable if parents maintain a rigorously smoke-free environment and avoid using NRT during pregnancy and breastfeeding.
2 hours for nicotine) (4) . Cotinine penetrates tissues more extensively than nicotine and lowers the heart rate (HR) and blood pressure (BP) of adults, effects that are opposite to nicotine itself (5) (6) (7) . Cotinine has a different mode of action to nicotine: evidence suggests it is a positive allosteric modulator of the naturally occurring acetylcholine receptor (nAChR) hence potentiates the responsiveness of nAChRs to, and sensitises tissue to the effects of, natural ligands (acetylcholine, choline) and agonists like nicotine (8) . On this basis, it might reasonably be expected that prolonged perinatal exposure to cotinine will have some consequences. Here, we undertook the first systematic effort to differentiate possible long-term effects of earlylife exposure to cotinine from those of its parent alkaloid nicotine.
To model low-level, human maternal-foetal (in utero, via the placenta) and mother-to-newborn (ex utero, via breast milk) exposure to cotinine or nicotine we used mice. Our aim was to simulate, as realistically as possible, cotinine's potential perinatal actions. In principle proof that cotinine is more than just an inert biomarker of recent exposure to nicotine and/or second-hand smoke (SHS) has broad public health implications, in terms of global efforts to eradicate all avoidable mother-infant SHS exposure (1), as well as perhaps for pregnant smokers who contemplate using nicotine replacement therapy (NRT) to quit (9) . Based on World Health Organization estimates of the prevalence of SHS exposure, up to 40% of infants and children globally receive a stubbornly, alarmingly high ongoing cotinine load via indirect and/or direct ingestion of nicotine exhaled by smokers (10) . Recommending NRT to pregnant or breastfeeding women as 'safe and effective' and calls to raise the current dosage regimen because it 'does not work well enough' (11) may also need to be reconsidered if NRT's main by-product cotinine can be shown to have unrecognised adverse developmental side effects.
METHODS
The experiments were approved by the Karolinska and Bologna University ethics committees for animal experimentation and were conducted according to the principles expressed in the Declaration of Helsinki.
Mice and drugs
C57Bl/6J dams (3-4/cage) drank water laced with 2% saccharin (CTRL), or 2% saccharin+100 lg/mL nicotine freebase (N PRE ; Sigma Aldrich) or 2% saccharin+10 lg/mL cotinine [Pre+postnatal cotinine (C PRE ); Sigma Aldrich, C5923] for three weeks prior to and six weeks after mating (i.e. exposure was continuous, commencing at conception and ceasing at or shortly after weaning); cotinine at this dose matched the blood level of N PRE dams (Fig. 1A ). An additional cohort [Postnatal cotinine (C POST )] drank 2% saccharin+30 lg/mL cotinine for three weeks exclusively after birth until weaning, to achieve de novo postnatal-only exposure equivalent to that of the other litters. Saccharin (a sweetener) was added to drinking water to mask the bitter flavour of nicotine and cotinine. Drug-laced drinking water was refreshed twice weekly.
Experimental protocol
Tail blood (100 lL) was collected from anaesthetised dams 3 weeks after drug exposure started and again immediately postpartum. Some N PRE and C PRE pups were sacrificed on the day of birth or on postnatal day 10 for pooled trunk/ heart blood collection; tail blood (100 lL) from anaesthetised C POST pups was collected on postnatal day 20, that is just prior to weaning. Blood was centrifuged (2000 rpm 9 10 minutes at 4°C) and plasma kept at À80°C until assayed (Mouse/Rat Cotinine ELISA, Calbiotech). Weaned pups were kept under a 12:12-hour light-dark cycle (lights on at 9 AM) at 25°C with free access to drug-free drinking water and food (4RF21; Mucedola, Settimo Milanese, Italy).
Phenotyping
At 17 AE 1 weeks, male pups (to avoid confounding effects of oestrus) from CTRL (n = 6), C POST (n = 6), C PRE (n = 8) and N PRE (n = 9) dams were anaesthetised (1.8-2.4% isoflurane-O 2 + Carprofen 0.1 mg sc; Pfizer Italy) and implanted with electroencephalography (EEG)/neck electromyography (EMG) electrodes and a telemetric arterial BP transducer (TA11-PAC10, DSI, Tilburg, Netherlands) (12) . The transducer tip was advanced via the femoral artery into the abdominal aorta just caudal to the renal arteries. After~2 weeks recovery, each mouse pup underwent a standard EEG/EMG/BP morning recording in a whole body plethysmograph consisting of 5 hours habituation (chamber continuously purged with air) followed immediately by~2 hours intermittent mild asphyxia during sleep (chamber purged with five cycles of 15 minutes 13%O 2 +2% CO 2 -10 minutes air) to simulate (over an extended time course) mild sleep apnoea and help to unmask underlying, 'silent' dysfunction (13) . Gas exiting the plethysmograph was continuously sampled (ML205 Gas analyser, ADInstruments).
Vascular reactivity
Once phenotyping was complete, aortas from the arch to just rostral to the renal arteries were harvested under deep anaesthesia, stored at 4°C in CO 2 -bubbled Krebs-HEPES (14) and despatched overnight from Bologna to Stockholm (one of six batches of vessels inadvertently lost in transit). The following morning 2-3 rings~1-mm-long cut sequentially in a caudorostral direction were mounted on tungsten pins (620 mol/L; Multi Wire Myograph, Aarhus, Denmark) suspended in Krebs buffer bubbled with 5% CO 2 -95% O 2 at 37°C (refreshed each 15 minutes). Rings were gently stretched co-axially (~5mN, optimal resting tension for 22-28 g mice), stabilised for 1 hours, then subjected to (i) 2 9 80 mmol/L KCl each 30 minutes to measure contractile force (mN) and tension corrected for segment length (mN/mm); (ii) cumulative doses of the adrenergic agonist phenylephrine (PHE) to assess reactivity; (iii) precontraction with 10 À6 mol/L PHE then stepwise doses of acetylcholine (ACh) to test endothelium-dependent relaxation; and (iv) 10 À4 mol/L sodium nitroprusside (SNP) to elicit full, endothelium-independent relaxation.
Quantitative real-time polymerase chain reaction mRNA expression Carotid arteries harvested in tandem with aortas were kept at À80°C until RNA extraction (RNeasy Plus Universal Mini Kit, Qiagen, Italy). From 60 ng/sample converted to cDNA, we compared the expression of seven genes involved in smooth muscle contraction-relaxation (GoTaq â 2-Step RT-qPCR System, Promega, Sweden), using forward and reverse primers designed to span the exons of each gene via Web-based software (http://www.kegg.jp/kegg-bin/ highlight_pathway?scale=1.0&map=map04270&keyword =smooth%20muscle%20contraction; Table 1 ). The mRNA of the seven targets -the adrenergic a1D receptor (ADR), Ltype high-voltage-gated Ca 2+ channel a1 subtype (HVCC), Ras homolog-A GTPase (RhoA), protein kinase C (PKC), myosin light chain kinase (MLCK), Rho kinase (ROCK) and myosin phosphatase inhibitor protein (CPI-17) -was expressed relative to a reference gene (b-actin) known not to be intrinsically affected by nicotine at the dose used. We used an i-Cycler IQ5 (Bio-Rad) and annealing T = 60°C, except for HVCC, CPI-17 and PKC (T = 57°C to reduce nonspecific amplification); specific amplification for each primer pair was assessed from the melting curves at the end of each assay.
Analysis and statistics
Sleep state was scored as described previously (12) . Movement (MVT) was artefact ≥1s (13). We calculated beat-tobeat systolic (SBP), diastolic (DBP), pulse pressure (PP) and HR, instantaneous breath rate (f) and weight-adjusted tidal (V T ) and minute (V E ) volumes (Labchart v7, AD Instruments) (12) . The initial two asphyxia cycles invariably disrupted sleep so were excluded. The nonrapid eye movement ('quiet') sleep steady-state response (SSR) was the 11th-15th minute of the 3rd-5th asphyxia cycles inclusive (excluding MVTs and epochs of other states). The BP of one pup was excluded due to telemetry malfunction. We used a two-factor ANOVA with drug exposure and gas (air/ asphyxia) as factors, then Bonferroni-adjusted t-tests if the omnibus p < 0.05. Cotinine was analysed nonparametrically (Mann-Whitney/Kruskal Wallis test). As cotinine's toxicity is a fraction of nicotine's (2, 8) and C POST mice received the lowest cumulative cotinine exposure, cumulative dosage was qualitatively expressed as CTRL<C POST <C PRE <N PRE (xaxis Fig. 4B ). From each vascular dose-response curve fitted by nonlinear regression (GraphPad Prism V6, San Diego, CA, USA), we determined log concentration at halfmaximal response (EC50). ACh-induced relaxation is shown % precontraction. The mRNA ratios are shown relative to b-actin (DDCt method). Data are means AE SEM.
RESULTS
Litter size and birth weight were comparable across groups, although C PRE males were heavier at age~four months (Table 2) .
Cotinine transfer to pups -high before, low after birth The mean cotinine level of N PRE dams was less than reported for the same oral regimen (15) but matched that of C PRE dams (Fig. 1B) . Cotinine in foetuses exposed in utero fell by~80% after birth presumably due to elimination of Dams given a higher oral cotinine dose for 3 weeks after giving birth had >threefold higher blood levels vs. other dams (2 in panel C). Cotinine in blood from a subset of newborns exposed from conception plummeted after birth (3 in panel D, arrow; p = 0.015) presumably due to loss of placental transfer. Litters exposed exclusively to cotinine sequestered in milk (C POST ) had blood levels at weaning equivalent to the postnatal minimum of both litters exposed from conception (4 in panel D).
Means AE SEM. placental transfer (low-level exposure continued via milk; Fig. 1D ). As anticipated, plasma cotinine levels were highest in C POST dams, but their pups received (via milk) de novo exposure roughly equivalent to the postnatal minimum of both other groups (Fig. 1D) . Cotinine was undetectable in CTRL dams or pups.
Sleep-wake behaviour: unchanged by perinatal drug exposure Quiet sleep consolidated with each bout of asphyxia ( Fig. 2A-B ) and prevailed during cycles 3-5 ( Fig. 2C ). Total and average duration of MVTs disrupting sleep cycles 3-5 ( Fig. 2D-E) was comparable across groups, indicating a key protective-defensive response to an impending threat was essentially intact after exposure to nicotine or its metabolite.
Cotinine: devoid of respiratory side effects but slows the heart and lowers BP Exposure to nicotine (but not cotinine) produced a persistent, underlying hyperpnea (tidal and minute volumes consistently~17% and~6% greater, respectively, vs. all other groups; Table 2 ). Asphyxia elicited the same relative increase from all pups ( Fig. 3A-B ; SSR~7%/group; p = 0.9) due to 'rapid-shallow' breathing (Fig. 3D) . Cotinineexposed mice were mildly but significantly bradycardichypotensive at rest, but nicotine lowered only PP (narrower systolic-diastolic gap; Table 2 ). The typical circulatory response to asphyxia -a reciprocal rise in HR/fall in BP (Fig. 4A) -was evident in nicotine-treated but not cotininetreated mice: the latter's BP response was weak (C PRE ) or absent (C POST ) (Fig. 4B1-B2 ). In short, as cotinine's effects on BP control were opposite to nicotine's, the doseeffect curve was nonlinear/an inverted U-shape (1) (Fig.  4B1-B2 ).
Cotinine weakens adrenergic vasoconstriction, nicotine impairs vasodilation KCl-induced depolarisation-Ca 2+ influx-smooth muscle contraction revealed that vessels from N PRE mice generated intrinsically greater tension (Fig. 5A) . Activation by PHE The expression of seven genes involved in carotid artery smooth muscle contraction-relaxation was compared: the adrenergic receptor (a1-ADR), L-type highvoltage Ca 2+ channel (HVCC, a1 subtype), Ras homologA GTPase (RhoA), protein kinase C (PKC), myosin light chain kinase (MLCK), Rho kinase isoform 1 (ROCK-1), myosin phosphatase inhibitor protein (CPI-17). Primers were designed using Web-based software (http://www.kegg.jp/kegg-bin/highlight_pathway? scale=1.0&map=map04270&keyword=smooth%20muscle%20contraction). showed comparable adrenergic hypocontractility of N PRE and C POST vessels (right-shift in dose-response curves, twofold higher EC50; p < 0.0003; Fig. 5B ; similar but nonsignificant shift for C PRE ). Precontracted CTRL and cotinine-treated but not N PRE vessels relaxed normally with ACh (Fig. 5C ), whilst SNP completely relaxed all vessels. In short, endothelial dysfunction was attributed to nicotine but vascular hypocontractility to cotinine.
Cotinine reciprocally regulates two key genes involved in smooth muscle contraction PKC mRNA expression was consistently lower (p = 0.025; Fig. 5D ) and ADR mRNA higher overall (p = 0.05; Fig. 5E ) in all drug-treated vessels (no significant change in expression of other gene targets). This finding suggests that the vascular hypocontractility attributed to nicotine was actually secondary to an intracellular signalling anomaly due to low-level exposure to its main metabolite cotinine.
DISCUSSION
'Dosis sola facit venenum -the dose alone makes the poison' -has been a dictum of toxicology for 500 years (16) . Here we extend this principle to cotinine, long neglected and widely regarded as little more than a proxy measure of recent exposure to numerous other potential toxins in tobacco, including nicotine. Far from being inert, cotinine in fact has latent, highly selective actions on the immature heart and blood vessels, notwithstanding a normally wide safety margin, by virtue of prolonged tissue retention. Our conclusions are in line with human/rodent studies that show acute exposure of adults to this substance relaxes smooth muscle, widens blood vessels, attenuates adrenergic constriction, slows the heart and dose-dependently lowers BP (6, 7, 17, 18) . These actions may in fact be so effective in counteracting the sympathetic excitation-hypertension-tachycardia of nicotine as to explain why the BP of habitual smokers is often lower (not higher) than nonsmokers (19) . The surprising, novel findings from our modelling of short-term, perinatal exposure to cotinine are that its effects emerge very early-on, at blood levels equivalent to the lowest reported, and represent a legacy of past (not recent or ongoing) exposure, that is cotinine's cardiovascular consequences endure long after it has disappeared from the environment.
Some natural substances are toxic in small amounts, others harmless except at high doses. Our Figure 2 Cotinine -no effect on sleep and arousal. The protocol is summarised (A). Body movements lasting ≥1 second (MVT) initially disrupted quiet sleep but were shorter and less frequent with each asphyxia cycle (B; blue arrow). Nonrapid eye movement ('quiet') sleep predominated after the 2nd bout of asphyxia (C; % final 5 minutes of asphyxia cycles 3-5, groups combined for clarity), from which the steady-state response (SSR) to asphyxia was determined. Total (D; % cycles 3-5) and average MVT duration (E) indicates a key protective reflex that triggers/initiates arousal from sleep was functionally intact in all drug-exposed litters. Means AE SEM.
exclusion strategy -administer both drugs (N PRE ), withdraw one (C PRE ) and narrow the period of exposure (C POST ) -reveals how the onset, duration and blood level (i.e. cumulative effective dose) of a major tobacco by-product can have discrete and/or overlapping developmental effects that dwarf the hypothetical risks of many more potent trace constituents of tobacco. Our key findings are as follows: exposure to a low cotinine dose for a short time after birth reprogrammes cardio-circulatory function; a higher cumulative dose for longer (from conception) has a qualitatively similar impact. The inference is clear: the newborn is exquisitely vulnerable to this substance. Why is uncertain, but xenobiotic actions depend on many things, including maturity and gender. Our findings are timely given the global extent of inadvertent maternal-infant exposure to cotinine via multiple overlapping routes. The blood of newborns of passive smokers contains~3 ng/mL cotinine, and urine of infants living with at least one smoker~25 ng/ mL cotinine (1) (urine levels are~sixfold higher than blood) (4). This minimum average exposure may well understate the net cotinine load in many communities (20) . So, our modelling in mice is realistic and may even be conservative, that is understate cotinine's true developmental potential. How do parent alkaloid and its metabolite interact? Although not addressed in great detail, we do show that exposure to both from conception can generate a 'hybrid' phenotype: classical nicotine-like side effects -on breathing (21) endothelial function, possibly vascular structure -combined with enduring, cotinine-like side effects (vascular hypocontractility); subtle effects of cotinine -on resting BP and HR -seem to fade or are masked. Interaction effects are unpredictable: our empirical model suggests simply that for nicotine 'a little goes a long way', for cotinine 'less is more'.
Cotinine appears to impair vascular tension, reactivity and tone by downregulating the activity of an enzyme (PKC) that relays and amplifies messages from the cell surface to the interior, and which is a key player in cell homoeostasis and disease pathogenesis (22) . Low PKC activity is only one explanation for the loss of adrenergic reactivity we observed (right-shift in vascular reactivity curves and~twofold higher EC50). We do not rule out other deficits in smooth muscle sensitising pathways, although we found none. PKC has diverse, tissue-specific actions: it promotes actin-myosin binding and vascular smooth muscle contraction, modulates activity of ion channels and pumps, hormone and neurotransmitter release, gene expression, protein and DNA biosynthesis, and cell differentiation, proliferation, migration and growth. Conceivably therefore altered PKC activity could have other long-term cardiovascular (e.g. remodelling, proliferative, atherogenic) consequences (23) . Precisely how cotinine exerts its effect on PKC is unclear. Sustained overactivation by low dietary levels of natural plant toxins can 'turn-off' (deplete) signalling-competent PKC and blunt the contractile response to catecholamines (noradrenaline, adrenaline) and adrenergic agonists like nicotine (21, 24) . Loss of signal coupling to smooth muscle contractile proteins may initiate a compensatory upregulation of the membrane (adrenergic) receptors that mediate sympathetic vasoconstrictor/pressor reactivity to 'rebalance' the system (25) , but this may not fully reverse a hypocontractile/hypo-adrenergic state or restore BP ( Fig. 5D-E ; Table 2 ). Of course, mRNA levels are only indicative of transcriptional gene regulation: with limited tissue available, we did not show that cotinine downregulates PKC (and upregulates ADR) proteins. Changes in large elastic conduit vessels (the aorta) are not necessarily representative of the microcirculation; however, PKC does regulate the calibre of these small resistance vessels, so the mechanism we propose is broadly consistent with cotinine's ability to lower BP (Table 2 ). Nicotine's actions are more extensive and profound by virtue of its strong affinity for a ubiquitous, neuronal nAChR subtype which modulates catecholamine release from perivascular nerves and into the bloodstream (13, 21) . Its cytotoxicity is also driven by the release of reactive O 2 species that impair endothelial NO production and weaken arterial dilationrelaxation and causes smooth muscle cells to proliferate and secrete connective tissue (26) . A thicker, stiffer (N PRE ) vessel may contract more forcefully when treated with an agent that bypasses cell surface adrenergic receptors to directly depolarise/flood the cell with Ca 2+ (Fig. 5A ). The small arteries and arterioles are normally partially constricted at rest; this basal tone reflects a balance between factors that contract and relax the underlying smooth muscle -a process fundamental for matching blood flow to changing systemic and regional demand. Functional hyperaemia -dilation of local capillary-arteriolar networks and upstream supply arteries in metabolically active muscles -is the reason why BP falls slightly during systemic hypoxia. Cotinine's effect of weakening basal tone and shifting the prevailing balance towards vasorelaxation may explain the lower HR and BP observed at rest (Table 2) and also mitigate any local hypoxic vasodilatory effects (Fig. 4) . A slower HR and longer cardiac filling-time may be partial reflexive compensation for reduced cardiac filling and output (hence a lower resting BP, as the heart only pumps blood it receives). Whether cotinine slows the heart directly or indirectly has not yet been established (7) .
The classic connotation of toxicology ('the science of poisons') is how chemicals and biology interact. With only a fraction of nicotine's potency, cotinine may be less likely to elicit undesirable side effects, but its actions need careful scrutiny to ensure it is not toxic by other mechanisms. The parallel between the circulatory changes we attribute to cotinine in mice and the remarkably similar, subtle deficits described in newborns who breathe low-level smoky air for a few months (1) is so striking that it suggests an answer to the question we posed at the outset: circulatory dysfunction in early infancy is plausibly, conceptually linked to lowlevel, short-term exposure to cotinine. Subtle, underlying deficits in circulatory control during sleep have a variety of important pathophysiologic implications in infancy (27) (28) (29) . Those for whom these findings are especially relevant are the many millions of pregnant women and their infants regularly, avoidably, exposed to cotinine (mainly via SHS), as well perhaps as advocates of the therapeutic virtues of NRT during pregnancy and/or breastfeeding as a quitsmoking strategy (11) . Is it really 'safer' to administer pure nicotine to a pregnant mother as a strategy to avoid tobacco's numerous other impurities (9)? Is it less harmful to consume one chemical which has significant circulatory side effects inextricably linked to its principal metabolite?
CONCLUSIONS
Cotinine is more than simply a benign biomarker of recent perinatal exposure to tobacco and tobacco smoke: some side effects of nicotine can plausibly be attributed to this ubiquitous metabolic by-product. Our findings suggest that the goals of all adult smoking cessation strategies should be broad: to reduce, preferably to eliminate completely, all foetal and infant exposure to nicotine and its metabolites. Cells reprogrammed -by cotinine as well as by nicotinemay never completely revert to their original state: 'All changed, changed utterly: a terrible beauty is born' (30) . Figure 5 Vascular reactivity and gene expression Nicotine-treated vessels contracted with more force in response to direct (K + -mediated) depolarisation-Ca 2+ influx (A). Reactivity to phenylephrine (PHE) revealed pronounced adrenergic hypocontractility of nicotine and cotinine-treated vessels (right-shift of all curves vs. CTRL; B). Precontracted cotinine-treated vessels relaxed normally with acetylcholine (ACh) and sodium nitroprusside (SNP; C), but N PRE showed evidence of endotheliumdependent dysfunction. The mRNA expression ratios are shown relative to b-actin. PKC mRNA levels were consistently~three-to sixfold lower (D; overall p < 0.025) and adrenergic receptor (ADR) levels marginally higher (E; overall p = 0.05). Conclusion: adrenergic hypocontractility develops after birth due to a cotinine-related signalling anomaly affecting two key genes located upstream from the smooth muscle contractile proteins. Means AE SEM.
